DanPET AB is comitted to develop future biomarkers and medicines in areas where there is an unmet need - In collaboration with World Leading Partners.

DanPET focus on PET-ligands and medicines with nicotinic and monoamine mechanisms for diseases such as Alzheimer’s, Parkinson’s, ADHD and Cancer. PET is a nuclear medicine technique for non-invasive, real-time 3D-imaging of physiological processes in the brain and other organs.